CSL.AX ASX
CSL Limited
1W: -0.9%
1M: +1.2%
3M: +41.5%
YTD: +2.3%
1Y: -14.9%
3Y: -32.6%
5Y: -39.2%
A$175.91 ($122.31)
-2.33 (-1.31%)
Weekly Expected Move ±3.5%
A$163
A$169
A$175
A$182
A$188
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#1
of 61
Biotechnology
Technical Signal Map
4 Bullish
0 Neutral
9 Bearish
CSL.AX
$84B
CSL Limited
BULLISH
+40
SPL.AX
$330M
Starpharma Holdings Limited
BULLISH
+60
OCC.AX
$210M
Orthocell Limited
BULLISH
+43
PYC.AX
$1.5B
PYC Therapeutics Limited
LEAN BULL
+25
NEU.AX
$2.5B
Neuren Pharmaceuticals Limited
LEAN BEAR
-16
CUV.AX
$420M
Clinuvel Pharmaceuticals Limited
BEARISH
-32
TTX.AX
$340M
Tetratherix Ltd.
BEARISH
-42
RAC.AX
$360M
Race Oncology Limited
BEARISH
-58
MSB.AX
$2.7B
Mesoblast Limited
BEARISH
-66
ACW.AX
$220M
Actinogen Medical Limited
BEARISH
-68
TLX.AX
$5.3B
Telix Pharmaceuticals Limited
BEARISH
-75
NYR.AX
$120M
Nyrada Inc.
BEARISH
-78
DXB.AX
$140M
Dimerix Limited
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| CSL.AX CSL Limited | $84B | -23.1 | 3.2 | 24.2 | -40.2 | 10.1 | 6 | BULLISH | -14.9 |
| SPL.AX Starpharma Holdings Limited | $330M | -46.8 | -83.3 | -940.8 | -725.1 | 50.8 | 5 | BULLISH | 627.3 |
| OCC.AX Orthocell Limited | $210M | -14.3 | -115.5 | 317.8 | -145.3 | 66.2 | 3 | BULLISH | -33.3 |
| PYC.AX PYC Therapeutics Limited | $1.5B | -41.6 | -24.2 | -43.7 | — | -38.0 | 4 | LEAN BULL | 93.7 |
| NEU.AX Neuren Pharmaceuticals Limited | $2.5B | 128.1 | 61.3 | 282.1 | 14.6 | 7.2 | 5 | LEAN BEAR | 6.7 |
| CUV.AX Clinuvel Pharmaceuticals Limited | $420M | 11.9 | 29.5 | 261.9 | 41.1 | 13.9 | 5 | BEARISH | -21.7 |
| TTX.AX Tetratherix Ltd. | $340M | — | — | — | — | — | — | BEARISH | 60.9 |
| RAC.AX Race Oncology Limited | $360M | -31.0 | -58.0 | -593.7 | — | -24.2 | 3 | BEARISH | 57.4 |
| MSB.AX Mesoblast Limited | $2.7B | -32.0 | -9.9 | -14.4 | -23.4 | 614.6 | 5 | BEARISH | 5.2 |
| ACW.AX Actinogen Medical Limited | $220M | -11.2 | -146.6 | -360.9 | — | -63.0 | 1 | BEARISH | 107.7 |
| TLX.AX Telix Pharmaceuticals Limited | $5.3B | 109.7 | 14.8 | 5.8 | 8.0 | 201.8 | 5 | BEARISH | 10.1 |
| NYR.AX Nyrada Inc. | $120M | -19.0 | -156.0 | -1212.7 | — | -48.7 | 3 | BEARISH | 100.0 |
| DXB.AX Dimerix Limited | $140M | -4.5 | -2512.0 | 178.2 | -619.9 | 2106.2 | 3 | BEARISH | -50.0 |
| CSL.AX CSL Limited | $84B | -23.1 | 3.2 | 24.2 | -40.2 | 10.1 | 6 | BULLISH | -14.9 |
| SPL.AX Starpharma Holdings Limited | $330M | -46.8 | -83.3 | -940.8 | -725.1 | 50.8 | 5 | BULLISH | 627.3 |
| OCC.AX Orthocell Limited | $210M | -14.3 | -115.5 | 317.8 | -145.3 | 66.2 | 3 | BULLISH | -33.3 |
| PYC.AX PYC Therapeutics Limited | $1.5B | -41.6 | -24.2 | -43.7 | — | -38.0 | 4 | LEAN BULL | 93.7 |
| NEU.AX Neuren Pharmaceuticals Limited | $2.5B | 128.1 | 61.3 | 282.1 | 14.6 | 7.2 | 5 | LEAN BEAR | 6.7 |
| CUV.AX Clinuvel Pharmaceuticals Limited | $420M | 11.9 | 29.5 | 261.9 | 41.1 | 13.9 | 5 | BEARISH | -21.7 |
| TTX.AX Tetratherix Ltd. | $340M | — | — | — | — | — | — | BEARISH | 60.9 |
| RAC.AX Race Oncology Limited | $360M | -31.0 | -58.0 | -593.7 | — | -24.2 | 3 | BEARISH | 57.4 |
| MSB.AX Mesoblast Limited | $2.7B | -32.0 | -9.9 | -14.4 | -23.4 | 614.6 | 5 | BEARISH | 5.2 |
| ACW.AX Actinogen Medical Limited | $220M | -11.2 | -146.6 | -360.9 | — | -63.0 | 1 | BEARISH | 107.7 |
| TLX.AX Telix Pharmaceuticals Limited | $5.3B | 109.7 | 14.8 | 5.8 | 8.0 | 201.8 | 5 | BEARISH | 10.1 |
| NYR.AX Nyrada Inc. | $120M | -19.0 | -156.0 | -1212.7 | — | -48.7 | 3 | BEARISH | 100.0 |
| DXB.AX Dimerix Limited | $140M | -4.5 | -2512.0 | 178.2 | -619.9 | 2106.2 | 3 | BEARISH | -50.0 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
CSL.AX vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F